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Abstract
Recent findings support an indirect relationship between T cell depletion in HIV-1 infection and the rate of virus replication with
implications for treatment strategies. We have initiated a new approach to recover immune function through the use of novel chemical
agents. A cationic amphiphilic drug that binds to Ca2-calmodulin at high concentrations, [10-{3-(4-methyl-1-piperazinyl)-propyl}-2-
(trifluoromethyl)-10H-phenothiazine dihydrochloride] [denoted trifluroperazine dihydrochloride (Tfp); molecular weight 480.43] TFP was
found at low concentrations (106 to 1010 M) to help T cells from AIDS patients to restore proliferation in vitro. Here we show that the
Tfp molecule can restore the cell survival of T lymphocytes from PBMCs derived from HIV-1-infected patients in vitro. Tfp enhances T
cell proliferation and Th-cell responses by selectively inhibiting cell mortality and apoptosis. The restored antigen-specific response is
associated with the synthesis of IL-2 and -interferon. Even though this drug does not possess any detectable antiviral effect, it might be
considered as a potential therapeutic agent in HIV-infected patients, to correct immune defects. Besides antiviral compounds, these data may
facilitate immune reconstitution in patients with HIV infection and other immunosuppressive diseases.
© 2003 Elsevier Inc. All rights reserved.
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Restoration of the immune system is a crucial element in
the successful clinical management of human immunodefi-
ciency virus (HIV)-1 infection. Current therapy for HIV
infection consists of highly active antiretroviral therapy
(HAART) and protease inhibitors, which are presumed to
exert their positive effects on CD4 T cell number and
immune function by inhibiting viral replication (Autran et
al., 1997; Pakker et al., 1998). However, the clinical benefits
of HAART still have limitations, namely HIV-1-infected
persons receiving HAART have responded with partial res-
toration of immune cell populations (Bohler et al., 1999;
Hengel et al., 1999), immune functions (Autran et al., 1997;
Dam-Nielsen et al., 1998; Ledermann et al., 1998), and
homeostasis (Dyrhol-Riise et al., 1999). Immune recovery
generally appears incomplete and variable. Many additional
strategies to reconstitute the immune system during
HAART have been attempted (Pantaleo, 1997; Butera,
2000), including the in vivo expansion of the T cell popu-
lation with the use of interleukin-2 (Chun et al., 1999) and
the development of novel chemical agents (Achour et al.,
1998; Achour, 2001, 2002; Butera, 2000).
A remarkable chronic immune activation is observed in
HIV-1-infected individuals throughout infection leading to
lymphadenopathy and dysregulated expression of various cy-
tokines (Clerici et al., 1993; Copeland and Heeney, 1996).
Impaired proliferative responses (anergy) and increased apop-
tosis of activated T lymphocytes are the hallmarks of the
pathogenesis characteristic of HIV-1 infection. The difficulties
associated with the use of agents that induce proliferation of
CD4 T cells, the major reservoir of HIV-1, which in turn
leads to increased viral replication limits the therapeutic use-
fulness of these approaches involving immune reconstitution.
Several hypotheses have been suggested to explain the deple-
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tion of CD4 T lymphocytes (Zinkernagel and Hengartner,
1994). The model of high lymphocyte turnover has been pro-
posed postulating that HIV-1 infection leads to a rapid turnover
of lymphocytes (Ho et al., 1995; Wei et al., 1995). It has been
reported that per`ipheral T cell proliferation is a consequence of
generalized immune activation (Hazenberg et al., 2000). The
activation of HIV-1 expression and viral production, in addi-
tion to the limited clonogenic potential of the uninfected T
cells, represents the two major obstacles for CD4 T cell
proliferation. Moreover, infection with HIV-1 results in a re-
markable loss of cell-mediated function. The virus infects
CD4-positive cells inducing lysis of infected lymphocytes and
releasing virions. However, direct killing of infected cells can-
not account by itself for the progressive immune deficiency
characteristic of AIDS. It has been recently reported that CD4
cell depletion is directly associated with immune activation
and only indirectly to viral load (Broussard et al., 2001; Deeks
et al., 2000; Kaur et al., 1998). Infection with HIV is associated
with apoptosis, which is partially responsible for the depletion
of CD4 T cells, independent of virus-mediated cytolysis
(Finkel et al., 1995). AIDS is also characterized by an impair-
ment of the immunoregulatory network (Fauci, 1993).
In a previous study we have studied cationic amphiphilic
drug effect in the form of AY 9944 molecule and provided
a new target for manipulation of immune responses. We
have shown that AY 9944, a nonspecific calmodulin antag-
onist, can restore the expression of the IL-2 receptor and
Th-cell responses, favoring cytokine and chemokine pro-
duction (Achour et al., 1998; Achour, 2000). In this study,
we report the activity of another cationic amphiphilic drug
[trifluoroperazine dihydrochloride (Tfp)] for its anti-HIV-1
activity in peripheral blood mononuclear cells (PBMC) de-
rived from healthy HIV-1- seronegative individuals and
chronically infected AIDS patients. This molecule belongs
to the series of antipsychotic agents, phenothiazines, pos-
sessing a wide range of pharmacological action (Breugnot et
al., 1990; Jeding et al., 1995; Slater, 1968). Tfp binds to
calmodulin in the presence of calcium and inhibits its effect
at high concentrations (Hait and Lee, 1985; Levin and
Weiss, 1977; Nel et al., 1986). We found that this com-
pound, at low concentrations (where anticalmodulin effects
are not observed), was able to reduce HIV-induced disor-
ders. More importantly, the drug appears to restore the
survival of T cells by decreasing cell mortality and apopto-
sis. The development of Tfp-based treatment that can re-
store immune functions may offer a complementary ap-
proach to AIDS therapy besides anti-HIV compounds.
Results
Effect of the drug on mitogen-induced proliferative
responses of PBMC from healthy seronegative individuals
Tfp inhibited the growth of cells, including lymphocytes
at high concentration of the drug. Thus, cells grew normally
at 106 M Tfp but showed 90% inhibition at 105 M. To
assess the biological effects of Tfp at lower concentrations,
we studied the proliferative responses of PBMC after in
vitro activation with phytohemagglutinin (PHA). PBMC
derived from four healthy seronegative donors were either
infected in vitro with HIV-1 or not infected. Following 10
days in culture, the number of viable HIV-1-infected PBMC
(Fig. 1A) was significantly lower in the untreated controls as
compared with noninfected cells (Fig. 1B). Moreover, when
PBMC were cultured in the presence of Tfp (from 106 to
1010 M), the proliferative responses of the infected PBMC
were significantly higher than the untreated cells (P 
0.001). The survival of HIV-1-infected PBMC increased by
2.9- to 4.9-fold (at day 14) with 106 to 1010 M TFP (peak
response at 108 M). In noninfected PBMC a lower but
significant (P  0.001) change in the survival rate was
found following culture with Tfp. At 14 days of culture, the
survival increased by 1.1- to 2-fold (Fig. 1B). The number
of untreated living cells in the HIV-1-infected cultures pro-
gressively decreased as a consequence of infection (Fig. 1A,
control). In contrast, when these cells were cultured in
media containing Tfp, the reduced survival of in vitro HIV-
infected PBMC was corrected to the level seen in cultures of
uninfected cells in the presence of the drug (Figs. 1A and
B). Such a beneficial effect of Tfp on the survival of PBMC
(50% of the maximal effect at 5  1010 M) appears to be
within the range of pharmacological concentrations (Fig.
1A). The mechanisms by which TFP increased cell survival
might be at either the level of T cells or the level of adherent
cells (AC). To address this question, nonadherent CD4 T
cells and CD8 T cells from healthy donors were purified.
No increase in cell survival was observed when CD4,
CD8, or CD4 and CD8 cells were cultured in absence
of adherent cells (Table 1). Moreover, preincubation of
(AC) with an inhibitor of protein synthesis (actinomycin D),
completely abolished the Tfp effect (Table 1).
Since HIV-1 replicates in activated cells and Tfp in-
creases cell survival, primary concern with the use of Tfp in
cultures of HIV-infected cells might be that such cultures
would result in an increase in target cells and thus increased
viral burden. As shown in Fig. 1C, no consistent changes in
viral production in the PBMC, as evaluated by serial mea-
surement of P24 antigen, were detected during the culture.
At 18 days of the culture cells treated with the drug exhib-
ited a decline in P24 antigen levels. However, from 8 to 20
days, P24 antigen levels in the supernatant was not signif-
icantly different from those in untreated cells (Fig. 1C). A
quantitative PCR was also performed to determine amounts
of HIV proviral DNA. Whereas HIV-1 Gag proviral DNA
became detectable in all cultures at early time points, by day
14 and 17 days PBMC treated with Tfp molecule showed a
slight decrease in HIV gag DNA (more than twofold).
However, expression of HIV gag DNA was comparable in
all the samples at 20 days of culture (Fig. 1D).
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Effect of the drug on PBMC from naturally infected
patients
To compare the results obtained with cells obtained from
healthy individuals, lymphocytes were cultured from four
patients (P1, P2, P3, P4) (CD4 counts from 196 to 664
cells/mm3, Table 2 ) with PHA and IL-2 to evaluate the
effect of the drug on naturally infected cells for 4 weeks. As
illustrated in Fig. 2, when T cells were cultivated with Tfp
(107 M), the cell survival increased by 2.5- to 6-fold more
than the control cells after 2 weeks of culture (P  0.001).
Compared to controls, PBMCs cultured in the presence of
Tfp demonstrated substantially decreased cell mortality re-
vealed by trypan blue exclusion (Figs. 2A–D). This reduc-
tion of mortality seems polyclonal and Tfp increased cell
proliferation of CD4 in the same level as CD8 T cells
(data not shown). In the PHA-stimulated culture, the data
revealed an initial expansion of treated cells at week 2,
resulting in termination on weeks 3 and 4 of the culture.
T cell anergy is a characteristic of HIV-1 infection. To
Fig. 1. Cells derived from four healthy HIV-1-seronegative individuals were either infected with HIV-1 (A, C, D) or not infected (B). Data represent the
cell-proliferation cultures from 3 to 20 days poststimulation of cells alone or in the presence of Tfp molecule (106 to 1010 M). Results are expressed as
the number of viable cells (means  SD) (A,B). Cell-free culture supernatants were analyzed for p24 ELISA (C) and quantitative proviral DNA was done
by PCR with 1  106 cells (D).
Table 1
Effects of adherent cells (AC) on the cell survival of T cells stimulated with PHA and cultured in the presence of 107 TFPa
Day 0 of culture Day 5 of culture Day 10 of culture
Medium TFP Medium TFP Medium TFP
Total PBMCs (AC)b 2 2 4 5 8 12
CD4 T cells (AC)c 2 2 3 3.5 4.9 5.2
CD8 T cells (AC)c 2 2 3.3 4 5 5.6
CD4  CD8 T cells (AC)c 2 2 4 4.5 5.4 6
CD4  CD8 T cells ( treated AC)d 2 2 3.9 4 5 5.6
a PPMCs were derived from healthy HIV-1 seronegative donors and cultured as described in Fig. 1.
b Data are expressed as the total number of viable cells.
c Nonadherent T cells were purified using the magnetic beads (Materials and methods).
d Inhibitor of protein synthesis Actinomycin D was added to AC prior to coculture.
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investigate this issue, we tested the ability of lymphocytes to
proliferate in vitro in response to CD3 stimulation in the
absence and presence of CD28 costimulation. First, lym-
phocytes from two patients (P5, CD4: 389/mm3 and P6,
CD4%: 554/mm3) were cultured with immobilized mono-
clonal antibody to CD3 and IL-2. Cell survival, the percent-
age of cell mortality, and the percentage of apoptotic cells
were compared during the first 2 weeks of culture in the
presence or absence of Tfp. The results shown in Fig. 3
revealed an initial expansion of cells from day 7 to day 9.
This pattern was coincident with decreased cell mortality
compared to untreated cells. However, by day 11 the pro-
portion of apoptotic cells diminished in TFP-treated cells
compared to untreated cells (30% variation, P  0.005).
In a second step, we tested the T cell receptor (TCR) and
the CD28 costimulatory signal engagement to amplify T
cell activation. We cultured lymphocytes from three pa-
tients with HIV-1 infection with CD3 mAb and CD28 mAb.
P9 is a recent HIV-1 seroconverter (CD4: 800/mm3, plasma
viral load: 50 copies/ml), whereas individuals P7 (CD4:
450/mm3, plasma viral load: 19778 copies/ml) and P8
(CD4: 41/mm3, plasma viral load: 6080 copies/ml) were
patients under treatment (Table 2). As shown in Fig. 4, at
10–20 days of culture, cell survival from two naturally
infected donors with clinical symptoms (P7 and P8) (Figs.
4A and B) were significantly lower than the response of
PBMC from asymptomatic individual P9 (Fig. 4C) (P 
0.001). Moreover, when cells were cultured in the presence
of Tfp molecule (106–1010 M) proliferative responses
from all individuals were significantly higher than in control
untreated cells. Under Tfp (107 M), cell survival of PBMC
from individuals P7 and P8 up regulated in the same range
as the cells from patient P9. After 2 weeks of culture, the
number of viable cells conditioned by Tfp molecule for the
donor P7 the donor P8 and the asymptomatic individual P9
were 55  106, 63  106, and 65  106, compared to
untreated cells (9  106, 8  106, and 30  106), respec-
tively (Figs. 4A–C). As seen in figs. 4A, B, and C, the
number of untreated living cells provided from patients (P7
and P8) progressively decreased. In contrast, when these
cells were supplemented with complete medium containing
Tfp molecule, the cell mortality remained low. Such a
beneficial action of Tfp on the survival or the mortality of
PBMC provided from HIV-1-infected donors was dose de-
pendent and fitted within the range of pharmacological
conditions as indicated in Fig. 4 (peak response at 108,
50% of the maximal effect at 1010 M). We further deter-
mined whether Tfp could also prevent naturally infected
PBMC from viral production. Since it is difficult to detect
p24 antigen in the cultures of lymphocytes from AIDS
patients, a quantitative PCR was used to determine amounts
of HIV-1 RNA. By day 7–16 of the culture, no specific
diminution in virus production was observed in cells from
patients P7 and P8 and no virus production was detected in
PBMCs originated from recent seroconverter individual P9
(data not shown).
Effect of the drug on the expression of Ki-67 antigen
To answer the question of whether increased T cell
proliferation could be involved in T lymphocyte depletion,
we measured expression of Ki-67 nuclear antigen, which is
expressed in late GI, SI, G2, and M phase of the cell
division circle in our cultures. After stimulation with mAbs
anti-CD3 and -CD28, PBMCs provided from two patients
(P10, CD4: 329/mm3; P11, CD4: 713/mm3) were cultured
in complete medium in the presence or absence of Tfp
(107 M). As shown, from day 14 of the culture, we ob-
served a decline in the percentage of Ki-67 lymphocytes
(Figs. 5A and B). In parallel, higher increases in the
percentage of cell survival and diminution of apoptotic cells
were observed. When cells derived from 10 patients were
studied, the expression of the cell-cycle marker Ki-67 and
the fraction of apoptotic decreased sigificantly after 14 days
of the culture in the presence of TFP (Table 3). Analysis by
flow cytometry indicated that the naive (CD45RA/
CD62L) and memory (CD45RO) subsets of both CD4
and CD8 T lymphocytes were equally expanded by Tfp
(data not shown).
Table 2
Patient characteristics
Patient no. CD4 counta Plasma viral loadb Antiviralc
P1 196 620 3TC, D4T,
PI
P2 561 6990 (—)
P3 664 692 3TC, D4T
P4 362 1842 (—)
P5 389 50 3TC, D4T,
PI
P6 554 50 DDC, D4T,
PI
P7 450 19,978 3TC, D4T
P8 41 6080 3TC, D4T,
PI
P9 800 50 (—)
P10 329 123 AZT, 3TC,
PI
P11 713 983 3TC, D4T,
PI
P12 600 146 3TC, D4T
P13 259 879 (—)
P14 811 50 3TC, D4T,
PI
P15 935 50 3TC, D4T,
PI
P16 353 49,178 3TC, D4T,
PI
P17 30 263,935 (—)
a CD4 T cells per mm3 of blood.
b Plasma HIV-1 RNA, copies per ml of plasma (commercial kit).
c Abbreviations: AZT, zidovudine; 3TC, lamivudine; D4T, stavudine;
PI, protease inhibitors; (—), without treatment.
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Fig. 2. Effect of Tfp molecule on the survival (total number of viable cells) (A, B, C, D) and the percentage of dead cells assessed by Trypan blue exclusion
(A, B, C, D) of PBMCs from four AIDS patients (P1, P2, P3, P4). After stimulation with PHA, PBMCs were cultured with (106 to 1010 M) or without
Tfp. Data are expressed as the means for triplicate cultures. The standard deviation was less than 10% of the mean.
Fig. 3. Effect of Tfp on the cell survival, the percentage of cell morality, and the percentage of apoptotic cells in cultured PBMCs stimulated with immobilyzed
mAb anti-CD3. Cells were derived from two patients [A, P5, CD4: 389/mm3 (A) and P6, B CD4: 554/mm3] and cultured with or without Tfp. For
apoptosis the results are expressed as the percentage of annexin-positive cells evaluated by the FITC-labeled annexin V assay. Data are expressed as the means
for triplicate cultures. The standard deviation was less than 10% of the mean.
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Fig. 4. Effect of Tfp on the cell survival and the percentage of cell mortality (106 to 1010 M) in cultured PBMCs stimulated with immobilized mAbs
anti-CD3 and -CD28. Cells were derived from patients P7 (A, A), P8 (B, B), and P9 (C, C) (Table 2) and cultured with or without Tfp. Each point represents
the mean of three experimental values. There was less than 7% variation among them.
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Fig. 5. Effect of Tfp on the cell survival (A,B), the percentage of Ki-67 T cells (A, B), and the percentage of apoptotic cells in cultured PBMCs stimulated
with immobilized mAbs anti-CD3 and -CD28. PBMC were originated from patients P10 (A, A, A) and P11 (B, B, B). Data are expressed as the means
for triplicate cultures. The standard deviation was less than 5% of the mean.
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Effect of the drug on recall antigen-, SEB-, and
HIV-peptide 18-induced proliferative responses of PBMC
It has been reported that HIV-1 individuals can be
divided into distinct groups, based on in vitro production of
IL-2 and proliferation in response to recall antigens and
PHA. Negative response to recall antigens is an early event
in HIV immune dysfunction compared to PHA. To deter-
mine whether Tfp would also increase T helper cell func-
tions to recall antigens as PPD, TT, and superantigen SEB
in individuals infected with HIV-1, we stimulated the
PBMC of six HIV-1 individuals (P12–P17) with these
antigens. The data of Fig. 6 illustrates that the proliferative
responses to SEB of PBMC from HIV-1 patients was
increased approximately 2- to 4-fold; their PPD responses
were increased 2- to 3-fold and TT responses were in-
creased 0.5- to 2-fold (P 0.005). Proliferation of unstimu-
lated cultures was not increased by Tfp.
Then, we also investigated the effect of Tfp on HIV
antigen similar to P18MN V3 loop envelope peptide. The
data of Fig. 7 indicate that the proliferative responses to
P18MN in PBMC of six HIV individuals was signifi-
cantly increased in the presence of Tfp. Compared to PBMC
activated with PHA or anti-CD3 and CD-28 and cultured
with recombinant IL-2, cells activated with antigens could
be a more physiological way to determine cytokine produc-
tion. We tested IL-2 and IFN production in response to env
P18MN peptide in fresh PBMCs derived from the same
HIV individuals. In these experimental conditions, when
fresh PBMCs were cultured with HIV-1 V3 loopP18MN
peptide in medium without recombinant Il-2, we observed
an increased expression of interleukin 2 at 3 days of culture
as determined by intracellular staining (increasing of 60 to
160%, P  0.005). The T helper effect of Tfp molecule
appeared to be associated with its selective capacity to
restore the IFN-dependent cell activation denoted by sig-
nificant augmentation of IFN- production. As indicated in
Fig. 7 P18MN-activated PBMCs from HIV-1-infected indi-
Table 3
Effects of TFP (107 M) on the apoptosis and membrane Ki-67
expression of HIV- infected patientsa (P8–P17, n 	 10) T cells
stimulated with anti-CD3/CD28
Day 7 of culture Day 15 of culture
Control TFP Control TFP
% apoptotic cells 31  6 28  7 35  9 17  7*
% Ki-67 T cells 43  8 39  9 35  8 19  5*
a Data are expressed as the mean  SD of the measurements.
* P  0.01 as compared with untreated control cells.
Fig. 6. Human peripheral blood Th-cell responses to recall antigens (PPD, TT) and to superantigen (SEB) in the absence or presence of Tfp (107 M).
Proliferation of PBMC from six HIV individuals (P12 through P17) in response to recall antigens (PPD, TT) and to superantigen (SEB), in presence of
Tfp (solid bars) or without Tfp molecule (clear bars). (Ag) indicates unstimulated cultures. Results represent mean  of triplicate cultures of [3H] uptake
at 6 days poststimulation.
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viduals treated in vitro with Tfp molecule showed a signif-
icant increase of IFN--producing cells from 100 to 300%,
compared to control cells cultured without the molecule (P
 0.001). This proliferative response evaluated through
3H-thymidine incorporation is also associated with cell sur-
vival as reflected by the significant increase of the number
of viable cells in presence of Tfp compared to control cells
after 6 days of culture (Fig. 7B).
Discussion
As calmodulin antagonist, Tfp inhibits cell proliferation
at high concentrations. This inhibition was observed within
a very narrow range of drug concentrations: cells grew
normally in 1 M Tfp and 90% inhibition occurred at 10
M and 95% at 50 M (Hait and Lee, 1985). Previous
studies have indicated that calmodulin antagonists such as
trifluoperazine and chlorpromazine inhibit the replication of
several RNA viruses including measles virus and influenza
viruses (Bohr et al., 1983; Krizanova et al., 1982; Ochiai et
al., 1991). It has been reported that Tfp inhibited AIDS virus
production from lymphocytes at concentrations that were
inhibitory for cell proliferation (Srinivas et al., 1994). Inhi-
bition of apoptosis in cells from AIDS patients and ceram-
ide-mediated apoptosis in Jurkat cells by Tfp at high doses
have also been reported (Micoli et al., 2000; Pan et al.,
1998). In the present study no specific inhibition of viral
production was observed at lower concentrations.
The clinical evolution in HIV-1 infection results from
immunosuppression characterized by T cell anergy, apopto-
sis, and chronic activation of T cells. T helper hyporespon-
siveness occurs in the context of generalized state of acti-
vation. This generalized immune activation is characterized
by an increased expression of Ki-67 expression. It has been
proposed that apoptosis could be a mechanism whereby
CD4 and even CD8 T cells can be killed in HIV-infected
individuals without invoking direct infection of the cells by
HIV-1 (Ameissen and Capron, 1991). The causal relation-
ship among CD4 cell depletion, HIV replication, and acti-
vation are not well understood. Recent reports indicate that
CD4 depletion during HIV/SIV infection is more directly
related to the activation than to the free virus (Broussard et
al., 2001; Deeks et al., 2000; Kaur et al., 1998). Therefore,
it has been suggested that elevated immune activation in-
duces T cell depletion but only indirectly to virus load
(Sousa et al., 2002). Depression of antigen-specific T cell
responses are also an important feature of HIV infection. It
involves a qualitative dysfunction of T cells (Fauci, 1993;
Clerici et al., 1993).
Here we show that cationic amphiphilic molecule Tfp, at
low concentrations (106 to 1010 M), can restore the
proliferation of the T lymphocytes. This restoration is ob-
served in T cells derived from patients receiving or not
Fig. 7. Effect of Tfp on T cell proliferative response (A), cell survival (B), intracellular production of IL-2 (C), and INF- (D) in cultured PBMCs (provided
from patients described in Fig. 6) stimulated with HIV-1 envelope peptide (P18 MN). Results represent mean of triplicate cultures at 6 days poststimulation.
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receiving HAART with variable CD4 counts and viral load
values. Tfp increases normal and HIV-1-infected T cell
survival after mitogen stimulation. This activity appears
indirect due to the synthesis of molecules by AC. An inhi-
bition of anergy was also observed after CD3/CD28 liga-
tion. As the consequence of restored T cell proliferation an
inhibition of apoptosis by Tfp is observed only in the second
week of culture. This inhibition of apoptosis is associated
with a decreased expression of the cell-cycle marker Ki-67.
Since increased expression of Ki-67 expression was caused
by generalized immune activation, TFP may facilitate the
reentry of the majority of T cells into the Go cell-cycle
phase. Tfp does not confer a specific protection against
HIV-1 in either levels of viral production and or proviral
DNA load. Ongoing work is aimed to study PBMC derived
from a large panel of patients with very low CD4 counts the
effect of Tfp in relation with the stage of HIV-1 infection.
It clearly appears in our experimental system that a
compound which is believed to be classical, “calmodulin
antagonist,” is efficient in preventing cell mortality and
restoring T cell proliferation in HIV-1 infection. The cat-
ionic amphiphilic structure of Tfp is characterized by a
bulky hydrophobic core associated with a nitrogen-linked
cation. In previous studies, we reported the ability of cat-
ionic amphiphilic molecules as being potential immuno-
stimulants for HIV-1 infection (Achour, 2001, 2002). More
recently, we have reported the immunomodulatory effects
of aminoperazine, a phenothiazine derivative able to in-
crease the antigen-specific dendritic cell proliferation (Lu et
al., 2001). Since -interferon and IL-2 production are in-
duced with Tfp under viral antigen stimulation, recovery of
proliferative response may be explained by the production
of other unknown growth factors regulating vital biological
processes such as regulation of immune responses and cel-
lular proliferation. Whether this activity and its associated
responses are due to the activation of T help 1 cells or reflect
the known activities of IL-12, IL-15, IL-18 on CD4,
CD8, NK, and antigen presenting cells remains to be
determined. The complete mechanism whereby Tfp modu-
lates these activities has to be elucidated. However Tfp
might independently of its action on calmodulin act on cell
metabolism by modifying the physicochemical characteris-
tics and the conformation of membrane structure (Maziere
et al., 1988).
Regarding clinical practice, the combination of these
molecules with HAART might represent a pharmacologic
mean for HIV-1 eradication. While our approach does not
target latently infected cells, it could enhance immune res-
toration to more efficiently eliminate latent infected cells
upon HIV-1 reactivation as suggested (Butera, 2000). Our
findings, therefore, suggest that Tfp molecule and related
molecules may represent an important candidate for thera-
peutic aimed the T cell functions in HIV-infected individ-
uals as well as in other immunosupressive diseases.
Materials and methods
Patients
Blood cells from 17 patients were experimented in this
study. Informed consent was obtained from all subjects as
reported previously (Lu and Andrieu, 2000). The character-
istics of patients were summarized in Table 2. Cells from
healthy HIV-1 seronegative individuals were obtained from
Lae¨nec Hospital (Paris, France). The study was performed
in accordance with local ethical committee standards.
Chemical
The Tfp molecule was provided by Sigma–Aldrich
(France).
Isolation of lymphoid cells
Lymphocytes were isolated from peripheral blood over a
Ficoll–Hypaque density gradient (Eurobio, France). In this
study our experiments were performed progressively with
freshly isolated PBMCs.
Cells and culture conditions
Heparinized venous peripheral blood was obtained from
HIV-1-seropositive adults with CD4 T cell counts ranging
from 100 to 950/mm3 and from HIV-1-seronegative healthy
controls. PBMC were isolated from heparinized venous
blood by Ficoll–Hypaque density gradient centrifugation
and were cultured in RPMI 1640 (Life Technologies,
France) supplemented with 10% heat- inactivated FCS
(Gibco, France), 2 mM L-glutamine (Sigma, Irvine, UK), 1
mM sodium pyruvate, and antibiotics (Sigma). PBMCs
were activated by phytohemagglutinin (Murex Biotech
Bradford, 1 g/ml) for 3 days. Thereafter the cells were
washed and cultured in the presence or absence of the drug
in complete medium supplemented with recombinant IL-2
(20 U/ml, Boehringer Gmbh, Germany). Cell seeding con-
sisted of 1  106 of viable cells per milliliter for 3 days of
culture. For stimulation with CD3 mAb or CD3 and CD28
mAbs (Pharmingen, Los Angeles CA), plates were coated
with antibodies (100 ng/ml) before adding PBMCs. Cells
were grown at 37°C in vented upright Costar 3065 flasks
containing 5 ml of culture medium. Cells were cultured for
3 days in the presence or absence of the drug and then
harvested for counting viable cell number by trypan blue
exclusion dye testing. To obtain nonadherent cells, PBMCs
were subjected to plate adherence for 12 h. Nonadherent
PBMC were enriched for lymphocytes and contained less
than 1% CD14 monocytes. Thereafter CD4 and CD8 T
cells were purified with the use of magnetic beads/DE-
TACH beads (Dynal, Great Neck, NY). To study mecha-
nisms, inhibitor of protein synthesis actinomycin D (0.1
g/ml) (Sigma, UK) was added to adherent cells for 12 h.
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Thereafter the cells were washed in RPMI and cocultured
with T lymphocytes.
In vitro infection of PBMC derived from healthy
individuals
PBMCs (5  106) were incubated with PHA for 48 h.
After washing, the lymphocytes were infected with 100
TCID50 of clinical HIV-1 isolate (S5) corresponding to a
non-syncytium-inducing (NSI) phenotype. After 2 h of in-
cubation, PBMCs were washed and cultured in complete
medium as described (Achour et al., 1998).
Lymphocyte proliferation
PBMCs collected from the patients blood were sus-
pended in culture medium [RPMI 1640 supplemented with
10% heat inactivated normal human (serum AB)] at 2.5 
106 cells per milliliters. One hundred microliters of the cell
suspension was added to 100 l of culture medium contain-
ing SEB superantigen (0.1 g/ml: Sigma, St. Louis, MO),
purified protein derivative (PPD, 3000 U/ml), tetanus toxoid
(TT, 1300 U/ml) or V3 loop P18 peptide (1 g/ml, Genosys,
London, UK) in the presence or absence of the drug. Plates
were incubated for 6 days, and during the last 18 h 0.5 Ci
3H-thymidine incorporation into DNA was measured. All
determinations were done in quadruplicate (Achour et al.,
1998).
Intracellular cytokine staining
After 3 days of culture, the cells were fixed in a final
concentration of 1% formaldehyde at 4°C overnight. Sub-
sequently they were washed in PBS and then in PBS con-
taining 2% FCS and 0.1% saponin (Sigma, St. Louis, MO).
PE-conjugated anti-IL-2 or anti-INF- mAb (Becton–Dick-
inson Immunocytometry Systems, San Jose, CA) in 30 l of
PBS/saponin was used to stain each sample for 60 min (30
min at 4°C followed by 30 min at room temperature). The
Ki-67 nuclear antigen, which is expressed in late G1, S1,
G2, and M phase of the cell division circle, is evaluated
using anti-Ki-67 PE (Pharmingen).
Apoptosis assays
Apoptotic cells were measured by FITC-labeled annexin
V, a phospholipid-binding protein that preferentially binds
to phosphatidylserine exposed at the cell surface in the early
phase of apoptosis using a commercially available kit (Im-
munotech, Luminy, France).
Immunofluorescence staining and flow cytometry
T lymphocyte phenotyping was carried out by flow cy-
tometry. Washed cells were analyzed on a flow cytometer
(FACS, Becton–Dickinson Immunocytometry Systems).
The variation in cell staining was calculated as [(% of
positive cells in treated cells) - (% of positive cells in
control cells) / (% of positive cells in control cells)] 
100%.
p24 enzyme-linked immunosorbent assay
The production of p24 antigen was measured by en-
zyme immunoassay. Tissue culture supernatants were
harvested and stored at 70°C until analysis. The com-
mercial kit used was Abbott (Abbott Laboratories, North
Chicago, IL, USA).
Viral quantification by PCR and reverse transcription
(RT)-PCR
Total DNA was isolated from 1  166 cultured cells by
using a DNA purification kit (Pre-A-Gene DNA Purification
Systems, Bio-Rad, Hercules, CA). RNA was extracted from
100 l of culture supernatants by using a commercial RNA
isolation solution (RNAzol; WAK-Chemie Medical, Bad
Hombourg, Germany). DNA and RNA were then amplified
by RT-PCR using adequate gag primers (Lu et al., 1999).
Amplified products were detected by using a solid-phase
technique. The absorbance of the samples was determined at
405/450 nm using a microplate Reader (Dynatech MRX,
Dynal, Great Neck, NY) and directly matched against the
standard curve.
Statistics
All results are expressed as means  standard deviations
(SD). Comparisons were done by Student’s t test. A P value
of 0.05 was considering significant.
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